Introduction#
Morgan Stanley has identified six prominent Chinese medical device manufacturers to keep an eye on as they approach their first-quarter earnings reports. The focus is on their potential for recovery, international growth, and product innovation.
Market Challenges#
The medical device sector is currently navigating a challenging environment, influenced by rising tensions between the U.S. and China, as well as slow domestic economic growth. Additionally, disruptions in supply chains and shipping, partly due to conflicts in the Middle East, could pose further challenges for these companies.
Key Companies to Watch#
Mindray Bio-Medical#
Morgan Stanley forecasts low single-digit sales growth for Mindray in the first quarter, with some relief from international sales. However, net profits may decline year-over-year unless foreign exchange losses are accounted for. Investors should pay attention to management's insights on recovery, future outlooks, inventory levels, and potential mergers.
Shanghai United Imaging Healthcare Co#
For Shanghai United Imaging, Morgan Stanley anticipates high teens percentage sales growth in the first quarter of 2026, despite a strong performance in the same period last year. The company is expected to see high single-digit profit growth, with minimal impact from the recent Middle East conflict on overseas orders.
APT Medical Inc#
APT Medical is projected to experience around 30% sales growth in the first quarter of 2026, driven by strong performance in its PFA segment. However, net profits may lag behind sales growth due to increased operating expenses related to promotions and research.
Shenzhen New Industries#
Shenzhen New Industries is expected to see a modest revenue increase in the first quarter, with flat sales growth in China and over 10% growth internationally. However, net profits are likely to decline year-over-year due to a challenging comparison with the previous year.
Imeik Technology Development Co#
Imeik faces ongoing pressures from competition and macroeconomic factors, which may affect its existing product sales. The company’s new wrinkle treatment, Hutox, is not expected to contribute to earnings until the latter half of 2026.